| Assessment Status | Rapid review complete |
| HTA ID | 22040 |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | For the treatment of chronic kidney disease |
| Assessment Process | |
| Rapid review commissioned | 08/06/2022 |
| Rapid review completed | 14/07/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dapaglifozin not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. August 2024
